Try-Lean warning letter
This article was originally published in The Tan Sheet
Executive Summary
Elroy, Wisc.-based Try-Lean is sent an FDA warning letter Aug. 31 for objectionable claims for its Try-Lean Formula 1 and 2, such as "reduce the risk of heart attack, reduce the risk of cancer, obesity, high blood pressure, ability to kill candida, anti-tumor, anti-bacterial action, wound healing, acne and anti-plaque build-up for dental health." In addition, a Web site and labeling for Calor-Slim make claims for treatment of arthritis, cataracts, glaucoma and diabetic retinopathy. Both products are unapproved new drugs, FDA says
|
Elroy, Wisc.-based Try-Lean is sent an FDA warning letter Aug. 31 for objectionable claims for its Try-Lean Formula 1 and 2, such as "reduce the risk of heart attack, reduce the risk of cancer, obesity, high blood pressure, ability to kill candida, anti-tumor, anti-bacterial action, wound healing, acne and anti-plaque build-up for dental health." In addition, a Web site and labeling for Calor-Slim make claims for treatment of arthritis, cataracts, glaucoma and diabetic retinopathy. Both products are unapproved new drugs, FDA says. |